Effects of crystalline nicotinic acid-induced hepatic dysfunction on serum low-density lipoprotein cholesterol and lecithin cholesteryl acyl transferase.
Marked lowering of plasma total and low-density lipoprotein cholesterol levels that occur during treatment of dyslipidemia with pharmacologic doses of nicotinic acid result from hepatotoxicity. Therefore, a marked reduction in low-density lipoprotein may suggest generalized liver toxicity and drug treatment should be discontinued.
Tatò
F
F
Department of Clinical Nutrition of the University of Texas Southwestern Medical Center and The Veterans Affairs Medical Center at Dallas, 75235-9052, USA.
Vega
G L
GL
Grundy
S M
SM
D000217:Acyltransferases / Q000378:metabolism*; D056486:Chemical and Drug Induced Liver Injury; D008078:Cholesterol, LDL / Q000097:blood*; D006801:Humans; D008099:Liver / Q000503:physiopathology*; D008107:Liver Diseases / Q000097:blood* / Q000503:physiopathology; D008111:Liver Function Tests; D008297:Male; D008875:Middle Aged; D009525:Niacin / Q000009:adverse effects*; D010713:Phosphatidylcholines / Q000378:metabolism*
D008078:Cholesterol, LDL; D010713:Phosphatidylcholines; D009525:Niacin; D000217:Acyltransferases; C029745:cholesteryl ester synthetase